XNAS · Healthcare · Biotechnology
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | Q1 2026 | -3.45 | -4.31 | -24.93% | $26,000 | ❌ Miss | +0.00% | -1.26% | — |
| 2026-03-12 | Q4 2025 | -5.02 | -3.84 | +23.51% | $2.5M | ✅ Beat | +3.53% | +12.10% | +21.23% |
| 2025-11-12 |
| Q3 2025 |
| -5.26 |
| -3.72 |
| +29.28% |
| $2.2M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-14 | Q2 2025 | -6.32 | -4.46 | +29.43% | $1.8M | ✅ Beat | -0.92% | -10.11% | -4.81% |
| 2025-03-24 | Q4 2024 | -0.38 | -0.38 | +0.00% | $0 | ➖ Inline | -4.02% | -8.59% | -14.99% |
| 2024-08-13 | Q2 2024 | -0.48 | -0.56 | -16.67% | $1.3M | ❌ Miss | -1.43% | -1.49% | -11.70% |
| 2024-05-14 | Q1 2024 | -0.51 | -0.28 | +45.10% | $5.3M | ✅ Beat | -37.12% | -41.29% | -41.73% |
| 2024-03-21 | Q4 2023 | -0.48 | -0.47 | +2.08% | $2.1M | ✅ Beat | — | — | — |
Showing last 8 quarters.